Market Insight - Stem cells: the unsteady rise of the East?
This article was originally published in Scrip
Executive Summary
South Korea has had an unsteady early relationship with stem cell research and the country has yet to recover fully from the high-profile Hwang Woo-Suk cloning scandal of 2006. This South Korean scientist famously and fraudulently reported to have succeeded in creating human embryonic stem (hES) cells by nuclear transfer. The scandal received widespread coverage in the media and dealt a terrible blow to the country on the embryonic stem cell research stage. Yet, the hero status bestowed on Dr Hwang before his downfall indicated that Asian governments supported, and that their communities were ready for, stem cell therapies.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.